UPDATE: Canaccord Genuity Initiates Coverage on Enzymotec Ltd. on Position to Drive Sustained Growth
In a report published Tuesday, Canaccord Genuity analyst Scott Van Winkle initiated coverage on Enzymotec Ltd. (NASDAQ: ENZY) with a Buy rating and $24.00 price target.
In the report, Canaccord Genuity noted, “We believe Enzymotec is well positioned to drive sustained growth in the highly attractive nutrition market, translating into strong sales, margin and earnings momentum. Its Vaya segment is purely an incremental opportunity not yet factored into the valuation.”
Enzymotec Ltd. closed on Monday at $17.81.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.